card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

Learn more
English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

Long-Term Disease-Free Survival in High Grade Serous Ovarian Cancer (HGSOC) is Dependent on Immune Microenvironment Characteristics of Primary Tumor

Application of RNA-based immune signatures in predicting disease-free survival
Home / Insights / Long-Term Disease-Free Survival in High Grade Serous Ovarian Cancer (HGSOC) is Dependent on Immune Microenvironment Characteristics of Primary Tumor

Patient outcome in high grade serous ovarian cancer (HGSOC) has had mixed success in associating the presence of intra-tumoral T cells and an “immunoreactive” subtype using RNA profiling. In particular, the TCGA OV study was not able to correlate expression-related immunogenicity with outcomes. Important factors associated with prognosis and long-term survivors of HGSOC include residual disease after cytoreductive surgery (RDCS), age and disease-stage.

In this poster, we explore 2 hypotheses:

  1. Primary: Primary tumors from HGSOC patients who have long-term disease-free survival (DFS) harbor a more active adaptive immune cell response.
  2. Secondary: The RNA-based immune signatures found following analysis of pan-cancer TCGA solid tumor samples have application to predict survival in independent cohorts od HGSOC and beyond.


Authors: Wendell Jones, IQVIA Laboratories; Mahrukh Ganapathi, Levine Cancer Institute; Chad Michener, Cleveland Clinic and Ram Ganapathi, Levine Cancer Institute

Complete the form below to access this scientific poster